ASCO 2026 Agenda: Schedule & Catalyst Tracker | BioMed Nexus

BioMed Nexus · Conference Intelligence

ASCO 2026 Tactical Agenda

Name: ASCO 2026 Annual Meeting (#ASCO26)
Start: 2026-05-29
End: 2026-06-02
Location: McCormick Place

Independent coverage · not affiliated with or endorsed by ASCO

Your field guide to the American Society of Clinical Oncology Annual Meeting (#ASCO26). Searchable, catalyst-aware, and filterable by day and disease track. Presidential theme: The Science & Practice of Translation — Improving Cancer Outcomes Worldwide.

📅 May 29 – Jun 2, 2026

📍 McCormick Place, Chicago

⌚ Central Time (CT)

👥 40,000+ attendees

Last updated: Sun, May 31, 2026 — Plenary results in

⚡ Catalyst Watch

Antibody-drug conjugates

Radiopharmaceuticals

Bispecifics & IO

AI in oncology

Plenary LBAs

ctDNA / MRD

Day

Track

Plenary Results — Live Sunday, May 31 · updated through the afternoon Plenary (CT)

This Weekend's Plenary: 5-for-5 on practice-changing data

LBA1

PROTEUS — perioperative apalutamide (Erleada) + ADT around prostatectomy, high-risk localized prostate cancer (J&J). Positive
Met both primary endpoints: ~9× higher pCR/MRD (8.9% vs 1.0%), 20% lower risk of metastasis or death. Published in NEJM. GU

LBA2

SARC041 — abemaciclib (Verzenio) vs placebo in advanced dedifferentiated liposarcoma (Lilly). Sarcoma — first CDK4/6 readout in this setting.

LBA3

LIBRETTO-432 — adjuvant selpercatinib (Retevmo) in resected stage IB–IIIA RET fusion+ NSCLC (Lilly). Positive EFS
Extends targeted adjuvant therapy into RET+ disease. Lung

LBA4

HARMONi-6 — ivonescimab + chemo vs tislelizumab + chemo, 1L squamous NSCLC (Akeso / Summit). Positive OS
OS HR 0.66; first China-originated drug in an ASCO Plenary. Published in The Lancet. Lung

LBA5

RASolute 302 — daraxonrasib (RAS(ON) inhibitor) vs chemo, previously-treated metastatic pancreatic cancer (Revolution Medicines, RVMD). Positive OS
Median OS 13.2 vs 6.7 mo, HR 0.40 (p<0.0001) — roughly doubled survival. Presented 3:21 PM CT; published in NEJM. GI / pancreatic

Results are company- and journal-reported (NEJM / The Lancet / JCO suppl). Figures are top-line; see each presentation and publication for full data. Use the Track filter below to jump to a tumor type.

Friday, May 29 Opening day · Education

1:00PM

Logistics

Meeting Officially Opens McCormick Place

Doors at 1:00 PM CT. In-person registration / badge pickup at Gate 3. Education Sessions run all afternoon across every tumor track.

1:00PM

Special Session

ASPO / Cancer Prevention Joint Session

1:00–2:30 PM CT. Joint programming with the American Society of Preventive Oncology.

1:00PM

Networking

JCO Publishing Workshop Room S103

1:00–3:15 PM CT. EIC Dr. Jonathan Friedberg + JCO editors. Limited attendance, in-person only.

ALL
DAY

Investor Watch

Abstract Intel: What's Already Public

Regular abstracts went live May 21 (5:00 PM ET) at asco.org/abstracts. LBAs stay embargoed until 7:00 AM CT on their presentation day — Plenary readouts won't hit the wire until Sunday morning.

Saturday, May 30 Opening Session · Science begins

AM
·
see app

Marquee

Opening Session

Presidential Address by Dr. Eric Small · Address from NCI Director Dr. Anthony Letai · David Karnofsky Award Lecture by Dr. Nancy E. Davidson. Confirm exact time & room in the ASCO app.

9:00AM

Logistics

Exhibit Hall Opens Hall A

9:00 AM–5:00 PM CT (Sat–Mon). Industry booths, pipeline demos, densest BD floor of the meeting.

ALL
DAY

Oral Abstracts

Oral & Rapid Oral Abstract Sessions

Tumor-track science across Lung, Breast, GI, GU, Heme, Melanoma & more. 23 Oral + 25 Rapid Oral + 13 Clinical Science Symposia over the meeting (450+ presentations).

10:00AM

Special Session

Cancer Care for Veterans

10:00–11:30 AM CT.

4:30PM

Special Session

ASPIRE: Immune-Related Adverse Events

4:30–6:00 PM CT.

4:45PM

Special Session

Best of JCO Global Oncology Room S403

4:45–6:00 PM CT. Affordability & access in resource-limited settings.

Sunday, May 31 Plenary Sunday · Peak catalyst day

1:00PM

Plenary · Results In

Plenary Session Reported

Sunday afternoon, ~1:00 PM CT (RASolute 302 / LBA5 at 3:21 PM CT). Five late-breakers — LBA1 PROTEUS (prostate), LBA2 SARC041 (liposarcoma), LBA3 LIBRETTO-432 (lung), LBA4 HARMONi-6 (lung), LBA5 RASolute 302 (pancreatic) — all reported positive top-line data. See the live results banner at the top of the page for figures.

9:00AM

Posters

Poster Sessions Hall A

Morning blocks begin 9:00 AM CT. 2,700+ posters across the meeting, incl. Trials in Progress — prime ground for early ctDNA/MRD and biomarker signals.

4:30PM

Special Session

Artificial Intelligence in Oncology

4:30–6:00 PM CT.

4:30PM

Special Session

Adolescent & Young Adult (AYA) Oncology

4:30–6:00 PM CT.

Monday, June 1 Business · Symposia

9:00AM

Logistics

Exhibit Hall — Final Day Hall A

9:00 AM–5:00 PM CT. Last booth meetings before teardown.

12:00PM

Networking

ASCO Annual Business Meeting Room S103

12:00 PM CT. Members' business meeting of ASCO and the Association for Clinical Oncology.

ALL
DAY

Oral Abstracts

Oral Sessions & Clinical Science Symposia

Continued tumor-track readouts plus 15 Case-Based Panels with live audience polling.

4:30PM

Special Session

RAISE: Radiopharmaceutical Alliance

4:30–6:00 PM CT. Hub for one of 2026's hottest catalyst themes (radioligand therapy spans GU/prostate & beyond).

Tuesday, June 2 Final sessions · Close

Oral Abstracts

Final Oral & Education Sessions

Closing-day science. Note: Exhibit Hall is closed Tuesday — the floor wraps Monday.

Logistics

Meeting Concludes

On-demand video, slides & transcripts remain available via the Program / ASCO app for registered attendees.

Side Events Receptions · KOL dinners · analyst events

Where the BD signal lives. The verified item below is public; the rest are recurring categories to populate from your invites and sell-side coverage. Most are badge- or invite-only — confirm with your covering analyst or host.

SUN
7:00PM

Reception

City of Hope Reception Verified Ritz-Carlton

Sun May 31, 7:00–8:30 PM CT, Ritz-Carlton Ballroom. Badge required; RSVP in advance.

SUN/
MON
EVE

Side Event

Sell-Side KOL Dinners Add

[Bank] — [Tumor focus] KOL dinner · [Venue] · [Time] CT · invite-only. Populate from analyst invites.

VAR

Side Event

Banker / IR Receptions Add

[Host] reception · [Venue] · [Day/Time] CT. Track for corporate-development conversations.

MON
AM

Side Event

Post-Plenary Investor Briefings Add

Pre-market breakfast briefings reacting to Sunday's Plenary reads · [Host] · [Time] CT.

Catalyst Tracker Confirmed #ASCO26 readouts

Now populated with this weekend's confirmed reads. Filter by Track above to isolate a tumor type. Figures are company/journal-reported top-line; Heme and Melanoma rows stay as watchlist prompts where no Plenary-level read landed this weekend — add more as oral/poster sessions roll through Mon–Tue.

LUNG

Lung

Lung — Plenary Reported

LIBRETTO-432 (LBA3, Lilly): adjuvant selpercatinib hit primary EFS in resected stage IB–IIIA RET fusion+ NSCLC.
HARMONi-6 (LBA4, Akeso/Summit): ivonescimab + chemo beat tislelizumab + chemo on OS in 1L squamous NSCLC, HR 0.66 (Lancet).

BRST

Breast

Breast — ASCENT-04 Tue Jun 2

ASCENT-04 (LBA1000, Gilead): sacituzumab govitecan + pembrolizumab vs chemo + pembro, 1L PD-L1+ metastatic TNBC. PFS data positive; presented Tue Jun 2, 9:45 AM CT (subgroup data in Rapid Oral, Sun 12:30 PM CT). Watch HER2-low ADC and PIK3CA (VIKTORIA-1) reads too.

GI — RASolute 302 Reported

RASolute 302 (LBA5, Revolution Medicines / RVMD): oral RAS(ON) inhibitor daraxonrasib vs chemo in previously-treated metastatic pancreatic cancer. Median OS 13.2 vs 6.7 mo, HR 0.40 (p<0.0001) — roughly doubled survival. Presented 3:21 PM CT; published in NEJM.

GU — PROTEUS Reported

PROTEUS (LBA1, J&J): perioperative apalutamide (Erleada) + ADT around radical prostatectomy in high-risk localized prostate cancer. Met both primary endpoints — ~9× higher pCR/MRD (8.9% vs 1.0%) and 20% lower risk of metastasis or death. Opened the Plenary; published in NEJM. Also watch RAISE / PSMA radioligand sessions (Mon).

HEME

Heme

Heme Watchlist Scaffold

Watchlist prompt: bispecifics in lymphoma/myeloma, CAR-T moving to earlier lines, BTK/BCL2.
[Company / Asset] — [Indication] · Abstract #— · [Session] · [Day] —:— CT · [Hall]

MEL

Melanoma

Melanoma / Skin Watchlist Scaffold

Watchlist prompt: TIL therapy, neoadjuvant IO, adjuvant mRNA-vaccine combinations.
[Company / Asset] — [Indication] · Abstract #— · [Session] · [Day] —:— CT · [Hall]

Tactical Intel Move faster than the crowd

📊

Data Timing

Abstract & Embargo Schedule

Regular abstracts: live since May 21, 5:00 PM ET. LBAs: 7:00 AM CT on presentation day. Map your watchlist to session days so you know exactly when each name unblinds.

📱

App

Build Your Live Schedule

Use the ASCO Meetings app or meetings.asco.org. Adding a session auto-enables push alerts — the fastest way to never miss a fixed-time read.

🎟️

Registration

Registration & Badge

McCormick Place, Gate 3. Register before arrival to skip the line. Badge required for most receptions and exhibits.

🚌

Getting Around

Shuttles & Transit

Complimentary shuttles to official ASCO hotels (except those adjacent to McCormick). A McCormick → O'Hare airport shuttle runs for departures — buy tickets onsite.

👟

Field Note

Survive 2.6M Sq Ft

McCormick is North America's largest convention center. Wear comfortable shoes and batch meetings by hall to cut walking time.

This Weekend's Plenary: 5-for-5 on practice-changing data

Meeting Officially Opens McCormick Place

ASPO / Cancer Prevention Joint Session

JCO Publishing Workshop Room S103

Abstract Intel: What's Already Public

Opening Session

Exhibit Hall Opens Hall A

Oral & Rapid Oral Abstract Sessions

Cancer Care for Veterans

ASPIRE: Immune-Related Adverse Events

Best of JCO Global Oncology Room S403

Plenary Session Reported

Poster Sessions Hall A

Artificial Intelligence in Oncology

Adolescent & Young Adult (AYA) Oncology

Exhibit Hall — Final Day Hall A

ASCO Annual Business Meeting Room S103

Oral Sessions & Clinical Science Symposia

RAISE: Radiopharmaceutical Alliance

Final Oral & Education Sessions

Meeting Concludes

City of Hope Reception Verified Ritz-Carlton

Sell-Side KOL Dinners Add

Banker / IR Receptions Add

Post-Plenary Investor Briefings Add

Lung — Plenary Reported

Breast — ASCENT-04 Tue Jun 2

GI — RASolute 302 Reported

GU — PROTEUS Reported

Heme Watchlist Scaffold

Melanoma / Skin Watchlist Scaffold

Abstract & Embargo Schedule

Build Your Live Schedule

Registration & Badge

Shuttles & Transit

Survive 2.6M Sq Ft

Join 65,000+ Biotech, MedTech, and Pharma Leaders

Your Daily Edge in Biotech, MedTech, and Pharma

Get trusted, high-signal updates every morningBreakthroughs, trial data, deals, and the news that matters

Get trusted, high-signal updates every morning
Breakthroughs, trial data, deals, and the news that matters